SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense volatility and social media chatter following critical comments from investor Michael Burry regarding the stock's valuation and the competitive threat posed by Anthropic. While the community is sharply dividedwith some viewing the sharp price decline as a classic market manipulation tactic or a buying opportunity, and others warning that the company's high valuation is unsustainablebulls continue to emphasize Palantir's entrenched position in government and defense infrastructure.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing significant downward pressure as investors rotate out of legacy SaaS stocks amid growing fears that AI agents from competitors like Anthropic could disrupt traditional software workflows. While the community remains deeply divided, with some investors panic-selling into 52-week lows and others aggressively accumulating on the belief that ServiceNow is undervalued and essential for enterprise AI, sentiment is currently dominated by bearish concerns over sector-wide repricing.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing significant speculative activity and high short interest, with investors closely watching the company's manufacturing scalability and production milestones to determine if the stock can sustain a recovery from recent lows. The community is deeply divided between long-term holders banking on a turnaround driven by grid storage demand and traders speculating on a short squeeze or a potential sharp pullback.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is capturing significant market attention following an expanded multi-year AI cloud capacity agreement with Meta, which investors see as a major vote of confidence in its scaling strategy. While some community members are cautious about the company's debt profile and financing activities, bullish traders are focused on the massive revenue visibility provided by long-term contracts and the ongoing demand for AI infrastructure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is actively dominating market conversation as news of a potential massive acquisition of Globalstar fuels speculation regarding its space and satellite-based connectivity ambitions. Simultaneously, the company is dealing with geopolitical volatility following reports of attacks on its cloud infrastructure, while investors closely monitor its aggressive data center investments and evolving chip strategy.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors weigh the stock's role in the 'agentic internet' infrastructure against broader volatility hitting the software and cybersecurity sectors. While the community remains divided over whether AI tools represent a competitive threat or a long-term demand catalyst for edge computing, many traders are actively debating re-entry points following the recent sector-wide repricing.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as the stock navigates significant volatility, with the community actively debating whether recent price action is a manipulative shakeout or a broader technical correction. Despite ongoing geopolitical uncertainty, long-term investors are highlighting the company's expanding AI infrastructure pipeline and anticipated data center lease announcements as core catalysts for future growth.

One & One Green Technologies, Inc. engages in the recycling, production, and trading of recycled scrap metals. Its products include copper alloy ingot, recycled aluminum, recycled tin, recycled zinc, recycled iron, and plastic beads. The company was founded on April 17, 2024 and is headquartered in Bulacan, Philippines.

One and one Green Technologies. Inc - Ordinary Shares - Class A

One and One Green Technologies Inc

One and One Green Technologies is drawing significant investor attention following its recent IPO, fueled by its unique position as a government-licensed e-waste processor in the Philippines and a low-float structure that has triggered high-volatility momentum. Community discourse is heavily split between retail traders eyeing potential for rapid upside in the materials sector and skeptics expressing caution over the volatility, liquidity challenges, and long-term sustainability of the company's operating model.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is experiencing heightened volatility as the market debates its AI-driven ad-tech moat against potential competitive pressures from major tech incumbents. While bulls point to strong free cash flow and expanding margins as evidence of undervaluation, bearish sentiment is being fueled by aggressive institutional put buying, executive selling, and ongoing concerns regarding the sustainability of the company's data-harvesting practices.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake Inc. is currently trending as investors debate the impact of AI on enterprise software valuations, with heavy volatility driven by technical breakdowns and intense options activity ahead of earnings. While some traders view the recent share price decline as a significant buying opportunity for a critical AI infrastructure provider, others express concern over increased competition and potential margin pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYDY from the man who got us MD Anderson:  48:15 Scott Kelly: 6/30/22 conference call: We believe we&#39;ve made significant progress on many fronts. Including search for CEO/President.  I want people to understand our thinking behind this. 2 examples. If you look at Humira, it stands for human monoclonal antibody in rheumatoid arthritis. It is one of the best selling drugs of all time. What Abby did which was so brilliant, was they took the target, TNF, tumor necrosis factor, and that target is important across multiple indications. They have 14 global and 10 US approved indications, and we are trying to do exactly the same thing. It is a very cost effective way to do drug development. Our target is the CCR5 receptor. If one looks at the literature, you will find that it has been implicated in many different indications, including HIV, NASH and oncology. So we will be actively pursuing partnerships to realize the true potential of LL in these indications. Thank you again for your time.

Andrew

Syco Dyne

Ji Ha

Mark Hayden

Maggie16

Robert

LIVIMMUNE Bound

The Goof

Steven feldman

Beachbumm

Thomas H Butcher

Chris Blad

Ferrero Rocher

Gary Edson, Ph.D.

John Fleming

Dustin Daigle

Paul King

steve

SzewczRock_79

lasallle

Bret (MyDangerDog on reddit)

Ryan Morrison

Jake

vivamiga

Phillip Longacre

D Rosen

StockTwits Web

CytoDyn Inc

 from the man who got us MD Anderson:  48:15 Scott Kelly: 6/30/22 conference call: We believe we've made significant progress on many fronts. Including search for CEO/President.  I want people to understand our thinking behind this. 2 examples. If you look at Humira, it stands for human monoclonal antibody in rheumatoid arthritis. It is one of the best selling drugs of all time. What Abby did which was so brilliant, was they took the target, TNF, tumor necrosis factor, and that target is important across multiple indications. They have 14 global and 10 US approved indications, and we are trying to do exactly the same thing. It is a very cost effective way to do drug development. Our target is the CCR5 receptor. If one looks at the literature, you will find that it has been implicated in many different indications, including HIV, NASH and oncology. So we will be actively pursuing partnerships to realize the true potential of LL in these indications. Thank you again for your time.

mitchmiller

scott kelly also said there are many ways to partner   
 
&quot;Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.&quot;

tom wright

150K_SHARES

scott kelly also said there are many ways to partner   
 
"Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center."

@MGK2 no one will partner with CYDY ever... you are too cowardly to explain why anyone would partner with CYDY knowing that... 
1. CYDY is a financial mess, i don&#39;t think i have to detail the gory details 
2. CYDY has demonstrated no ability to design and run a successful trial that shows efficacy 
3. CYDY does not have many key positions in place to show that they are a serious company... no safety, regulatory, biostatistics, data management, IT, CMO, etc... 
4. The SEC/DOJ are still lurking and they have a bad reputation with the FDA... 
5. CYDY hasn&#39;t dosed a patient in OVER A YEAR... do you know how embarrassing that is in the industry?!?!? 
 
Now, why don&#39;t you make the case for a partnership... do you want to start with &quot;because i want one&quot;????

Lauren

 no one will partner with CYDY ever... you are too cowardly to explain why anyone would partner with CYDY knowing that... 
1. CYDY is a financial mess, i don't think i have to detail the gory details 
2. CYDY has demonstrated no ability to design and run a successful trial that shows efficacy 
3. CYDY does not have many key positions in place to show that they are a serious company... no safety, regulatory, biostatistics, data management, IT, CMO, etc... 
4. The SEC/DOJ are still lurking and they have a bad reputation with the FDA... 
5. CYDY hasn't dosed a patient in OVER A YEAR... do you know how embarrassing that is in the industry?!?!? 
 
Now, why don't you make the case for a partnership... do you want to start with "because i want one"????

mazzy star

@mazzystar1 @MGK2 Come on, are you trying to say that even a company like Walden Biosciences would not even partner with Cytodyn?

 Come on, are you trying to say that even a company like Walden Biosciences would not even partner with Cytodyn?

M. O. E.

@Moes_their_leader @MGK2 what i have said all along is that no BP/biotech will partner with CYDY - they might be able to get a partnership with another small company whose molecule has failed in trials and are desperately looking to get back in the game... if there is any interest in LL by BP, it would be a buyout... CYDY does not add any value as a company and any BP would want to go it alone with the molecule... when a company does a DD background on a company, they pull everyone in the room who has been involved in the assessment and they discuss if it makes sense to pursue a partnership or a buyout... for a partnership, there has to be value from the company... CYDY hasn&#39;t proven that they are good at doing anything well... they are a financial mess and no company would want that headache... so there will be no partnership with any BP or leading biotech... schleppy companies like REGN, sure... i am still waiting for someone to make the case for a partnership besides &quot;i want one&quot;...

 what i have said all along is that no BP/biotech will partner with CYDY - they might be able to get a partnership with another small company whose molecule has failed in trials and are desperately looking to get back in the game... if there is any interest in LL by BP, it would be a buyout... CYDY does not add any value as a company and any BP would want to go it alone with the molecule... when a company does a DD background on a company, they pull everyone in the room who has been involved in the assessment and they discuss if it makes sense to pursue a partnership or a buyout... for a partnership, there has to be value from the company... CYDY hasn't proven that they are good at doing anything well... they are a financial mess and no company would want that headache... so there will be no partnership with any BP or leading biotech... schleppy companies like REGN, sure... i am still waiting for someone to make the case for a partnership besides "i want one"...

@mazzystar1 @MGK2 thanks for clarifying more.  I wanted to know about Walden Biosciences because you and you buddy tstone may have deeper insight.

StockTwits for iOS

 thanks for clarifying more.  I wanted to know about Walden Biosciences because you and you buddy tstone may have deeper insight.

@Moes_their_leader @MGK2 sorry... don&#39;t know anything specific about Walden... also, i don&#39;t have any &quot;buddies&quot; on this board - there are people whose posts i respect and many who i do not... i don&#39;t come here for friendship... i have enough real ones of those already...

 sorry... don't know anything specific about Walden... also, i don't have any "buddies" on this board - there are people whose posts i respect and many who i do not... i don't come here for friendship... i have enough real ones of those already...